CLINICAL TRIALS PROFILE FOR NAGLAZYME
✉ Email this page to a colleague
All Clinical Trials for NAGLAZYME
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00299000 ↗ | A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI | Completed | BioMarin Pharmaceutical | Phase 4 | 2006-05-01 | The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth. |
| NCT02156674 ↗ | Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome | Terminated | BioMarin Pharmaceutical | N/A | 2016-01-26 | This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant. |
| NCT02156674 ↗ | Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome | Terminated | Masonic Cancer Center, University of Minnesota | N/A | 2016-01-26 | This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NAGLAZYME
Condition Name
Clinical Trial Locations for NAGLAZYME
Trials by Country
Clinical Trial Progress for NAGLAZYME
Clinical Trial Phase
Clinical Trial Sponsors for NAGLAZYME
Sponsor Name
